Atai Life Sciences N.V.’s filing revealed that its 10% Owner Apeiron Investment Group Ltd. acquired Company’s shares for reported $97801.0 on Apr 29. In the deal valued at $4.47 per share,21,900 shares were bought. As a result of this transaction, Apeiron Investment Group Ltd. now holds 1,799,302 shares worth roughly $ 6.05 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Then, Apeiron Investment Group Ltd. bought 34,700 shares, generating $154,689 in total proceeds. Upon buying the shares at $4.46, the 10% Owner now owns 1,777,402 shares.
Before that, Apeiron Investment Group Ltd. bought 19,803 shares. Atai Life Sciences N.V. shares valued at $91,939 were divested by the 10% Owner at a price of $4.64 per share. As a result of the transaction, Apeiron Investment Group Ltd. now holds 1,742,702 shares, worth roughly $5.86 million.
Meanwhile, Maxim Group initiated its Atai Life Sciences N.V. [ATAI] rating to a Buy in a research note published on Tuesday, November 30, 2021; the price target was $25. PT values the company’s stock at a premium of 86.56 to its Tuesday closing price. A number of analysts have revised their coverage, including ROTH Capital’s analysts, who began to cover the stock in mid November with a ‘”a Buy”‘ rating. H.C. Wainwright began covering ATAI with a “Buy” recommendation on October 18, 2021. Jefferies started covering the stock on September 01, 2021. It rated ATAI as “a Buy”.
Price Performance Review of ATAI
On Tuesday, Atai Life Sciences N.V. [NASDAQ:ATAI] saw its stock jump 3.38% to $3.36. On the same session, the stock had its day’s lowest price of $3.31, but rose to a high of $3.47. Over the last five days, the stock has gained 10.89%. Atai Life Sciences N.V. shares have fallen nearly -55.96% since the year began. Nevertheless, the stocks have fallen -83.11% over the past one year. While a 52-week high of $22.91 was reached on 01/03/22, a 52-week low of $2.95 was recorded on 06/14/22. SMA at 50 days reached $4.05, while 200 days put it at $8.27. A total of 0.63 million shares were traded, compared to the trading of 1.01 million shares in the previous session.
Levels Of Support And Resistance For ATAI Stock
The 24-hour chart illustrates a support level at 3.29, which if violated will result in even more drops to 3.22. On the upside, there is a resistance level at 3.45. A further resistance level may holdings at 3.54. The Relative Strength Index (RSI) on the 14-day chart is 43.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.19%. Stochastics %K at 26.51% indicates the stock is a holding.
Atai Life Sciences N.V. [ATAI] – Who Are The Largest Shareholders?
. Over the last quarter, Pura Vida Investments LLC purchased 725,324 shares of Atai Life Sciences N.V., while BlackRock Fund Advisors bought 64,210 shares. At present, Woodline Partners LP is holding 763,896 shares valued at $3.04 million. Coeli Asset Management AB owned 600,000 shares of the company at the time of its most recent 13F filing, worth $2.39 million.
According to FactSet, Atai Life Sciences N.V.’s share price will average $26.60 in the next year, based on opinions of analysts polled by the firm. This is up nearly 653.85 percent from its previous closing price of $3.25. Analysts expect Atai Life Sciences N.V. stock to reach the higher price of $50.00, while the lowest price estimate is $8.00. However, 11 analysts have rated ATAI stock as a Buy in their predictions for 2022. The most recent change occurred on July 13, 2021 when RBC Capital Mkts began covering the stock and recommended ‘”a Sector perform”‘ rating along with a $19 price target.